Clostridium Diagnostics Market size was valued at USD 3.32 billion in 2024 and is anticipated to exceed USD 15.71 billion by the end of 2037, expanding at over 12.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of clostridium diagnostics is evaluated at USD 3.66 billion. The major factor to dominate the market expansion is the growing prevalence of clostridium-related disease mostly in low-income of developing nations. However, its prevalence could be also observed in developed nations including the United States. For instance, in the case of the United States, over half of a million infections are caused by C. diff.
Hence, worldwide, Clostridium difficile continues to pose an important risk to public health. Additionally, there has been a surge in various different variants posing a risk to human health. For instance, in addition to ribotype 027, which is known to be highly pathogenic, other strains such as 014/020, 017, 056, 106, and 078/126 have also been linked to C. difficile infection (CDI) and adverse health effects. The genetic composition, pathogenicity characteristics, antimicrobial susceptibility profiles, and geographic distribution of these strains vary, which may impact their capacity to spread disease and react to therapy.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
12.7% |
Base Year Market Size (2024) |
USD 3.32 billion |
Forecast Year Market Size (2037) |
USD 15.71 billion |
Regional Scope |
|
Technology (Immunoassays-Based Clostridium Diagnostics, Molecular Clostridium Diagnostics)
The immunoassays-based clostridium segment in the clostridium diagnostics market is projected to hold 60% of the revenue share during the forecast period. The major factor to influence the growth of the market is the rising use of antibiotics. A third (33%) of respondents to a WHO/Europe poll that was performed uniformly across the 14 countries reported using antibiotics without a prescription. Furthermore, antimicrobial resistance (AMR) constitutes one of the top ten global health problems, according to the WHO, and it is thought that bacterial AMR causes 5 million deaths globally each year. The concerning truth is that by 2050, AMR might cause up to 10 million deaths annually if nothing is done. This is why the demand for immunoassays-based clostridium segment is growing. Further, they offer good specificity, are convenient to use, and produce results quickly and affordably. It has grown more challenging to assess whether a patient needs therapy since a growing percentage of individuals with positive molecular testing for CDI do not appear to have the toxins that have traditionally defined the illness. Better outcomes and accurate diagnostics are driving demand for immunoassays, which will fuel market expansion over the projected timeframe.
End User (Hospitals, Government Diagnostics Laboratories, Independent Laboratories)
Clostridium diagnostics market from the hospitals segment is set to rise by gathering the highest revenue of about 50% over the forecast period. Hospitals have experienced this growth as a result of employing better diagnostic technology over time. The majority of hospitals have testing facilities on-site or in affiliation with another facility. The use of cutting-edge methods including immunoassay and molecular diagnostic technologies in hospitals has made it feasible to diagnose Clostridium in these clinical laboratories, which is further fostering the growth of this clostridium diagnostics market. Antibiotics such as vancomycin, carbapenems, benzylpenicillin, sulfonamides, tetracyclines, metronidazole, and metronidazole are also easily available in hospitals, which contributes to the segment's growth.
Our in-depth analysis of the global clostridium diagnostics market includes the following segments:
Technology |
|
End User |
|
Product |
|
North American Market Statistics
The North America clostridium diagnostics market is poised to hold 30% of the revenue share during the forecast period. This growth of this region’s market is set to be influenced by rising healthcare infrastructure. For instance, federal and household funding comprised the greatest portions of total health spending (33 and 28 percent, respectively). 18% of the total amount spent on health care was attributed to private company expenditure, 15% to state and local governments, and 7% to other private sources of income. Additionally, the pharmaceutical business in the United States produces numerous novel medications each year that offer significant medicinal benefits. Many of those medicines are pricey, which drives up the cost of healthcare for both the federal government and the private sector. Lawmakers have given thought to measures that would cut both federal drug spending and prescription prices. These regulations would most likely lessen the industry's motivation to create novel medications. Hence, with this the clostridium diagnostics market in the region is also projected to grow owing to the affordability of medication more people are estimated to opt for the diagnosis.
European Market Analysis
The Europe clostridium diagnostics market is also estimated to have notable growth during the forecast period. There has been shift in lifestyle in European people which is leading people to consume more health food. Additionally, this region has observed unhealthy practices of producing and storing food. Hence, these factors are leading cause of clostridium related illness in Europe which is further expected to influence the clostridium diagnostics market expansion.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?